Pediatric Neurologist Dr John Gaitanis Joins Kingdom Therapeutics’ Scientific Advisory Board

Kingdom Therapeutics has announced the appointment of Dr John Gaitanis of the Warren Alpert Medical School of Brown University, Rhode Island, to its Advisory Board to provide further insight into pediatric neurology.

Dr. Gaitanis joins an already robust Scientific Advisory Board where he will provide unique clinical insight into the pediatric population as Kingdom Therapeutics continues research on the link between the gut, the brain, and the endocannabinoid system, initially focusing on ASD.

A graduate of Brown Medical School, Dr. Gaitanis completed his neurology training at Children’s Hospital Boston. He went on to finish an epilepsy fellowship at Beth Israel Deaconess Medical Center before returning to Children’s Hospital Boston to join their epilepsy staff. While there, he co-founded the Comprehensive Brain Malformation Program, helping bridge clinical and basic science knowledge of these conditions.

In 2004, Dr. Gaitanis returned to Brown Medical School and Hasbro Children’s Hospital, where he served as the director of pediatric epilepsy. He aided in developing the ketogenic diet and epilepsy surgery programs at Brown. Between 2014 to 2022, he served as the Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children.  In 2022, he returned to Brown Medical School where he is now the director of Child Neurology.

Besides his clinical duties, Dr. Gaitanis serves on the board of directors of the Epilepsy Foundation of New England.

Dr. Gaitanis’ research aims to improve EEG sensitivity through digital signal processing. He has also published original articles and book chapters on status epilepticus, cortical malformations, and epilepsy in infancy and childhood.

When asked about the new appointment, David Howat, Chief Scientific Officer at Kingdom said:

“John will provide a unique perspective on the Scientific Advisory Board and his extensive work and in depth knowledge will assist us greatly in building on the foundations that we have in place already through our existing board of scientists and clinicians. The timing for John’s joining us is as we plan our Phase II study due to commence in the first half of 2023.”

Dr Gaitanis joins a panel of scientific advisors assisting Kingdom that spans the globe with members from Ireland, the United Kingdom, Canada, and Australia.